Show simple item record

Authordc.contributor.authorÁvila Smirnow, Daniela 
Authordc.contributor.authorVargas Leal, Carmen 
Authordc.contributor.authorBeytía Reyes, María de los Ángeles 
Authordc.contributor.authorCortés Zepeda, Rocío 
Authordc.contributor.authorEscobar, Raúl G. 
Authordc.contributor.authorKleinsteuber Saa, Karin 
Authordc.contributor.authorLagos Lucero, Marcela 
Authordc.contributor.authorAvaria Benapres, María de los Ángeles 
Authordc.contributor.authorPadilla Pérez, Oslando 
Authordc.contributor.authorCasar Leturia, Juan Carlos 
Authordc.contributor.authorMellado Sagredo, Cecilia 
Authordc.contributor.authorSternberg, Damien 
Admission datedc.date.accessioned2020-10-29T18:56:05Z
Available datedc.date.available2020-10-29T18:56:05Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationNeuromuscular Disorders 30 (2020) 554–561es_ES
Identifierdc.identifier.other10.1016/j.nmd.2020.04.006
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/177480
Abstractdc.description.abstractNon-dystrophic myotonias are a group of rare neuromuscular diseases linked to SCN4A or CLCN1 . Among the subtypes, myotonia permanens, associated with the Gly1306Glu variant of SCN4A , is a relatively less frequent but more severe form. Most reports of nondystrophic myotonias describe European populations. Therefore, to expand the genetic and phenotypic spectrum of this disorder, we evaluated 30 Chilean patients with non-dystrophic myotonias for associated variants and clinical characteristics. SCN4A variants were observed in 28 (93%) of patients, including 25 (83%) with myotonia permanens due to the Gly1306Glu variant. Myotonia permanens was inherited in 24 (96%) patients; the mean age of onset was 6 months, and the initial symptoms were orbicularis oculi myotonia in 17 (74%) patients and larynx myotonia in 12 (52%) patients. The extraocular muscles were involved in 11 (44%) patients, upper limbs in 20 (80%), and lower limbs in 21 (84%). Thirteen (52%) patients experienced recurrent pain and 10 (40%) patients reported limitations in daily life activities. Carbamazepine reduced myotonia in eight treated patients. The high frequency of the Gly1306Glu variant in SCN4A in Chilean patients suggests a founder effect and expands its phenotypic spectrum.es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherElsevieres_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceNeuromuscular Disorderses_ES
Keywordsdc.subjectMyotonia congenitaes_ES
Keywordsdc.subjectFounder effectes_ES
Keywordsdc.subjectApnoeaes_ES
Keywordsdc.subjectStrabismuses_ES
Keywordsdc.subjectLaryngospasmes_ES
Keywordsdc.subjectCarbamazepinees_ES
Títulodc.titleNon-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variantes_ES
Document typedc.typeArtículo de revistaes_ES
dcterms.accessRightsdcterms.accessRightsAcceso Abierto
Catalogueruchile.catalogadorlajes_ES
Indexationuchile.indexArtículo de publicación ISI
Indexationuchile.indexArtículo de publicación SCOPUS


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile